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Abstract
Background: Alcohol consumption is causally linked to nonadherence to antiretroviral treatment that in turn
causes an increase in HIV/AIDS mortality. This article presents a method to calculate the percentage of HIV/AIDS
deaths attributable to alcohol consumption and the associated uncertainty.
Methods: By combining information on risk relations from a number of published sources, we estimated alcohol-
attributable fractions (AAFs) of HIV/AIDS in a stepwise procedure. First, we estimated the effect of alcohol
consumption on adherence to antiretroviral treatment, and then we combined this estimate with the impact of
nonadherence on death. The 95% uncertainty intervals were computed by estimating the variance of the AAFs
using Taylor series expansions of one and multiple variables. AAFs were determined for each of the five Global
Burden of Disease regions of Africa, based on country-specific treatment and alcohol consumption data from 2005.
Results: The effects of alcohol on HIV/AIDS in the African Global Burden of Disease regions range from 0.03% to
0.34% for men and from 0% to 0.17% for women, depending on region and age category. The detrimental effect
of alcohol consumption was statistically significant in every region and age category except for the North Africa/
Middle East region.
Conclusions: Although the method has its limitations, it was shown to be feasible and provided estimates of the
impact of alcohol use on the mortality outcome of HIV/AIDS.
Background
Alcohol has been identified as a major risk factor for
mortality and burden of disease in past comparative risk
assessments within Global Burden of Disease studies
[1,2]. In past iterations of comparative risk assessments,
infectious diseases have not been included. However,
evidence has been accumulating that alcohol has a cau-
sal impact on infectious disease categories [3,4].
Evidence indicates a strong association between alco-
hol and HIV/AIDS [5,6], but personality variables such
as risk-taking or impulsive behavior cannot be excluded
as potential alternative explanations [6]. There is
sufficient evidence, however, that alcohol worsens the
course of the disease, especially by impacting adherence
to antiretroviral treatment. Globally, HIV/AIDS led to
about 2 million deaths and 58.5 million lost disability-
adjusted life years (DALYs) in 2004 [7]. Failing to esti-
mate the alcohol-attributable HIV/AIDS burden could
lead to substantial underestimation of the burden of dis-
ease and mortality attributable to alcohol.
Antiretroviral therapy has led to a change in the nat-
ural history of HIV [8-10]. Lima and colleagues have
shown that nonadherence to antiretroviral therapy by as
little as 5% has a significant effect on the mortality of
HIV-infected people in a high-income country [11]. Stu-
dies from low- to middle-income countries have shown
similarly elevated risks [12]. Therefore, adherence is a
key to the success of antiretroviral therapy, and
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necessary to maximize treatment benefits [13,14]. Poor
adherence to antiretroviral therapy is associated with an
increased likelihood of hospitalization [15], as well as
increased mortality [3,11,12,16].
Adherence is impacted by multiple variables such as
injection drug use, forgetfulness, suspicions about treat-
ment, complicated dosing regimens, number of pills
required, decreased quality of life, and work and family
responsibilities [17]. Alcohol use, and especially occa-
sions of heavy drinking, has been shown to have a
marked impact on adherence by interfering with one’s
capacity to plan for or remember dosing requirements.
In addition, alcohol users might have decreased access
to antiretroviral therapy or may use alcohol to reduce or
avoid HIV-related negative mood states [18]. A recent
meta-analysis [18] indicated that, compared to abstai-
ners, drinkers have an odds ratio of 0.604 (95% confi-
dence interval [CI]: 0.531, 0.687) of adhering at least
95% of the time to their treatment, meaning that those
who used alcohol were about 0.60 times as likely to be
classified as adherent to treatment as nonusers. Overall,
the effect of alcohol use on antiretroviral treatment has
been found to be causal [3,19].
Despite the demonstrated role of alcohol use on anti-
retroviral medication adherence, research on and model-
ing of the effect of alcohol use on the HIV/AIDS burden
of mortality and disease remain limited [20]. This article
suggests a method to quantify the fraction of HIV/AIDS
deaths attributable to alcohol consumption from nonad-
herence to antiretroviral therapy. We estimate the alco-
hol-attributable fraction (AAF) for HIV/AIDS-related
mortality by combining the effect of alcohol consump-
tion on antiretroviral adherence and the effect of adher-
ence on mortality. Therefore, this method only
considers increased mortality due to alcohol consump-
tion that is linked to a resulting worsened adherence to
antiretroviral treatment. It does not take into considera-
tion any effect that alcohol might have on the outcome
of HIV/AIDS in the absence of treatment. These causal
assumptions are summarized in Figure 1.
Methods
We conducted an analysis using data from the five Global
Burden of Disease (GBD) regions of Africa. These regions
were chosen for their high variation in both prevalence of
HIV/AIDS and adult per capita estimates of alcohol con-
sumption. These regions are defined as follows:
￿ North Africa/Middle East: Algeria, Bahrain, Egypt,
Iran, Iraq, Jordan, Kuwait, Lebanon, Libya, Morocco,
Occupied Palestinian Territory, Oman, Qatar, Saudi
Arabia, Syria, Tunisia, Turkey, United Arab Emi-
rates, Western Sahara, Yemen
￿ Sub-Saharan Africa, Central: Angola, Central Afri-
can Republic, Congo, the Democratic Republic of
the Congo, Equatorial Guinea, Gabon
￿ Sub-Saharan Africa, East: Burundi, Comoros, Dji-
bouti, Eritrea, Ethiopia, Kenya, Madagascar, Malawi,
Mayotte, Mozambique, Rwanda, Somalia, Sudan,
Tanzania, Uganda, Zambia
￿ Sub-Saharan Africa, South: Botswana, Lesotho,
Namibia, South Africa, Swaziland, Zimbabwe
￿ Sub-Saharan Africa, West: Benin, Burkina Faso,
Cameroon, Cape Verde, Chad, Côte d’Ivoire, Gam-
bia, Ghana, Guinea, Guinea-Bissau, Liberia, Mali,
Mauritania, Niger, Nigeria, Saint Helena, Sao Tome
and Principe, Senegal, Sierra Leone, Togo
Data sources
Country data on the proportion of people who are in
need of antiretroviral therapy and receive such treatment
were obtained for 2005 from the 2006 Report on the Glo-
bal AIDS Epidemic [21]. Regional data were then calcu-
lated as a population-weighted average. Table 1 outlines
the resulting regional proportion of people receiving anti-
retroviral treatment compared to all those who are in
need of such treatment for the five African GBD regions.
In order to establish the prevalence of nonadherence,
we adopted an estimate of 40.1% for the rate of nonad-
herence to antiretroviral treatment (95% CI: 36.9%,
43.3%), provided by Lima and colleagues [18,22]. This
estimate was between two other estimates of 47.6% and
31.8% for adherence rates of <80% and <90%, respec-
tively [12,16]. Please note that even though the relative
risk for people adhering to antiretroviral treatment com-
pared to people who are nonadherent is larger than the
relative risk for not being in treatment compared to
being in treatment, this does not mean that being in
Figure 1 Causal assumptions of our method of calculating
mortality due to nonadherence to antiretroviral therapy
because of alcohol use.
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ciated with worse outcomes than not being in treatment
at all. On the contrary, the risk relations between the
different groups based on the assumptions of Table 2
are as follows:
1 = risk of people in antiretroviral treatment adher-
ing on an arbitrary scale
3.13 = risk of people in antiretroviral treatment not
adhering to treatment
1.85 = risk of people in antiretroviral treatment
overall (assuming 0.401 nonadherent)
4.88 = risk of people not in treatment
Multiple sources were used to characterize the rela-
tionship between alcohol consumption and nonadher-
ence to antiretroviral therapy and the effect of
nonadherence on HIV/AIDS-related mortality. To char-
acterize the effect of alcohol consumption on antiretro-
viral adherence, we used the odds ratio of 0.60 (95% CI:
0.53, 0.69) from the meta-analysis performed by Hen-
dershot and colleagues [18,22] for adherence by global
drinkers (defined as alcohol consumption within the
past month) compared to abstainers. Since there have
been no meta-analyses of nonadherence on mortality,
we used a hazard ratio of 3.13 (95% CI: 1.95, 5.05) for
deaths of people not adhering to treatment (defined as
less than 95% of the time) compared to people adhering
to treatment, as reported by Lima and colleagues [11].
This estimate is similar to but slightly lower than the
hazard ratios of 3.2 and 3.9 for adherence rates of <80%
and <90%, respectively, as described in other studies
[12,16]. For the rate ratio of HIV/AIDS-related deaths of
people on antiretroviral treatment compared to people
not on treatment, we used a rate ratio reported by Mur-
phy and colleagues [23] that gives a point estimate of
0.38 (95% CI: 0.28, 0.52). These values were combined
to obtain the AAF for HIV/AIDS for a given population.
The following sections will first present the derivation
of the AAF for HIV/AIDS mortality from nonadherence
to antiretroviral therapy and then describe the derivation
of the 95% uncertainty intervals associated with these
AAFs. Estimations of uncertainty for the calculated
AAFs are of critical importance for the estimated bur-
den of disease attributable to alcohol and for policy
recommendations aimed at reducing this burden. Table
2 outlines the measures of association used to compute
the AAFs for the five African GBD regions and the pre-
valence of nonadherence to antiretroviral therapy for
those who are currently receiving antiretroviral therapy.
Derivation of AAFs for HIV/AIDS
Continuous modeling of the effects of alcohol use on
adherence [24,25] was impossible given the data avail-
able to us, and thus we limited our analysis to two
broad categories: drinkers versus nondrinkers, and anti-
retroviral therapy adherence (at least 95% of the time)
versus nonadherence.
The attributable fraction (AF) is defined as:
AF
PR R
PR R

 
  
1
11
where P represents prevalence of exposure and RR
represents the relative risk for exposure compared to no
exposure. Depending on the design of the original epi-
demiological study, the RR information could be derived
from hazard ratios, risk ratios, or odds ratios.
Table 1 Proportion of people in need of antiretroviral
therapy receiving antiretroviral therapy
Region Proportion
lower
bound
point
estimate
upper
bound
North Africa/Middle East 15.01% 17.36% 19.71%
Sub-Saharan Africa,
Central
3.00% 4.25% 5.50%
Sub-Saharan Africa, East 12.07% 14.24% 16.41%
Sub-Saharan Africa,
South
19.11% 21.67% 24.22%
Sub-Saharan Africa, West 11.36% 13.47% 15.59%
Table 2 Parameters used in calculating the AAF for people who die of AIDS due to nonadherence to antiretroviral
therapy
Parameter Symbol Value 95% Confidence
Interval
Source
Proportion of people on antiretroviral therapy who are not adhering to medication
regimen
Pna 40.1% (36.9% to 43.3%) Lima and colleagues
[22]
Risk ratio of nonadherence to antiretroviral therapy, comparing current drinkers to
abstainers
RRdrink 1.82 (1.63 to 2.04) Hendershot and
colleagues [18]
Mortality risk ratio for nonadherence to antiretroviral therapy compared to those
who adhere to antiretroviral therapy
RRna 3.13 (1.95 to 5.05) Lima and colleagues
[11]
Mortality hazard ratio for people not on antiretroviral therapy treatment compared
to those who are
HRnontreat 2.63 (1.92 to 3.57) Murphy and
colleagues [23]
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ing to antiretroviral therapy for people with HIV/AIDS,
the lack of research and limited information available on
the effects of alcohol on HIV/AIDS forced us to calcu-
late the AAFs for HIV/AIDS-related mortality in several
steps (for the definition and calculation of AAF in gen-
eral, see [26,27]).
First, we calculated the adherence attributable fraction
(AdAF) using a definition of nonadherence as adherence
to antiretroviral therapy less than 95% of the time. The
AdAF represents the fraction of HIV/AIDS-related
deaths attributable to nonadherence to antiretroviral
therapy, and is calculated as follows:
AdAF
PP R R
PP R R
adher na na
adher na na



1
where Padher is the proportion of people adhering to
treatment more than 95% of the time, Pna is the propor-
tion of people adhering to treatment less than 95% of
the time, and RRna is the relative risk of mortality for
those who are not adhering compared to those who are.
Second, we calculated the nonadherence due to alco-
hol attributable fraction (NAAAF) - the proportion of
nonadherence due to alcohol consumption - as follows:
NAAAF
PP R R
PP R R
abs drink drink
abs drink drink



1
where Pdrink is the proportion of drinkers among the
antiretroviral-treated HIV-infected population, Pabs is
the proportion of abstainers, and RRdrink is the relative
risk of nonadherence for drinkers compared to nondrin-
kers. Table 3 outlines the prevalence of current drinkers
by age and sex for the five African GBD regions.
Finally, we needed to know the proportion of deaths
of people under treatment compared to the total num-
ber of deaths in the population due to HIV infection.
Because the exact numbers are not known, we estimated
this proportion using the hazard ratio for deaths in peo-
ple without treatment compared to people with treat-
ment. This proportion of deaths of people undergoing
treatment (PDT) was calculated as follows:
PDT
P
PH RP
treat
treat nontreat nontreat


where Ptreat is the proportion of HIV-infected people
receiving treatment, Pnontreat is the proportion of HIV-
infected people not receiving treatment, and HRnontreat
is the hazard ratio of people without treatment. It
should be noted that hazard ratio and relative risk are
synonymous in this case. These three proportions can
be combined to calculate the AAF for HIV/AIDS mor-
tality for a given population.
AAF AdAF NAAAF PDT  
Estimation of the variance of AAFs
It is possible to derive a mathematical expression of the
variance of the AAFs when the variances of each para-
meter making up the final expression are known. Calcu-
lating the variance of the AAF of HIV/AIDS-related
mortality requires the combination of several steps.
Because these steps involve Taylor series expansions,
they yield only an approximation of the real variance.
We calculated the variance of the AAFs by calculating
the variance of the simplest combinations first, which
were then used in more complex functions. The deriva-
tions of the variance of two distributions and the deriva-
tion of the variances using Taylor series expansions can
be found in ‘additional file 1 appendix 1’.
In the literature, the uncertainty intervals for AFs due
to risk factors based on meta-analyses are usually com-
puted using a Monte Carlo-type method (for alcohol,
see [3]). The Monte Carlo method uses repeated ran-
dom samples of an AF to estimate its variance [28].
The AAF samples are obtained by randomly generat-
ing each parameter using the information we have on
its distribution. The main advantage of this method is
its broad range of applications. The method can be
applied to virtually any field and any function and is
especially useful in cases in which an algebraic solution
to a problem is impossible to derive. Our AAF, however,
is a relatively simple function of several independent
variables that makes the use of Monte Carlo samples
unnecessary. Indeed, an algebraic solution, when possi-
ble to obtain, should always be preferred to a simula-
tion, as the results are more precise and require fewer
resources. In fact, the results obtained with this method
are generated instantaneously on any computer and do
not require the use of servers or the handling of large
Table 3 Prevalence of current drinkers by region
Current Drinkers
Region Men (age in years) Women (age in years)
15 - 34 35 - 54 55+ 15 - 34 35 - 54 55+
North Africa/
Middle East
7.2% 12.0% 5.5% 3.5% 1.1% 0.4%
Sub-Saharan
Africa, Central
51.0% 51.9% 20.5% 32.4% 28.5% 11.9%
Sub-Saharan
Africa, East
24.6% 38.8% 37.2% 16.1% 24.9% 21.4%
Sub-Saharan
Africa, South
38.0% 38.0% 29.5% 12.6% 15.7% 9.8%
Sub-Saharan
Africa, West
36.2% 50.9% 40.5% 20.8% 31.2% 27.1%
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lysis. In addition, a decomposition of sources of varia-
tion and their relative contribution to overall variance
can be obtained more readily. Even though it is possible
to derive only an approximation of the variance of the
original function using second order Taylor series
expansions, the assumption that the spread of the func-
tion around its mean value is relatively small guarantees
an accurate result. The variations around the point esti-
mate of each AF function depend only on the variance
of the parameters used; therefore, knowledge of these
parameters is important. It should be noted that for
large variances of each parameter, the error in the var-
iance of the final function will increase as the assump-
tion of small variations is not satisfied. This is not
specific to the analytic expression derived here, but
would also affect a Monte Carlo method for which a
convergence would not be ensured unless a very large
number of data points are collected [29]. Finally, the use
of a second order approximation has the advantage of
yielding very simple expressions that combine only the
derivative of the function and the variance of its para-
meters; this means that they can be computed nearly
instantaneously in R using only a few command lines. It
should be noted that in many fields, such as electrical
engineering, quantum mechanics, and protein engineer-
ing, Taylor series of order two or fewer are used daily
and yield excellent results.
Variance of AdAF and NAAAF
Using the variances of Pna and RRna described in the
previous section, we derived a mathematical expression
for the variance of AdAF and NAAAF using Taylor ser-
ies expansions. The complete derivations can be found
in ‘additional file 1, appendix1’, and the final expression
of the variance of these terms is as follows:
For AdAF:
Var AdAF P RR
PR R
Var P RR
na na
na na
na na
[( ,) ]
()
[]

 
1
11
4
where
Var P RR Var P Var RR
RR Var P P Var RR
na na na na
na na na na
[, ] [][ ]
[] [


22 ] ]
And for NAAAF:
Var NAAAF P RR
PR R
Var P
drink drink
drink drink
dri
[( ,) ]
()
[

 
1
11
4 n nk drink RR ]
where
Var P RR
Var P Var RR
RR Var P
drink drink
drink drink
drink dr
[]
[] [ ]
[


2
i ink drink drink PV a r R R ][ ] 
2
Variance of PDT
The variance of the proportion of deaths of HIV-
infected people under treatment (PDT) cannot be
derived using the above methods. Since the variance of
PDT is a function of two variables, we used a Taylor
series expansion performed in two dimensions. These
derivations are shown in additional file 1, appedx1, and
the final expression of the variance is as follows:
Var PDT P HR
DV a r P
D
treat non treat
Pt r e a t
HR
treat
nontre
[, ]
[]
  

2
a at Var HRnontreat
2 []
where DPtreat and DHRnontreat are the partial derivatives
of the PDT function with respect to Ptreat and HRnontreat
and can be expressed as follows:
D
HR
PH R P
D
P
nontreat
treat nontreat treat
HR
treat
non tre



(( ) ) 1
2
a at
PP
PH R P
treat treat
treat nontreat treat



()
(( ) )
1
1
2
In this manner, the variances of all three components
of the final AAF function are determined. Using the var-
iances for AdAF, NAAAF, and PDT, the variance of the
AAF can be determined by the variance of (AdAF·-
NAAAF) PDT (see ‘additional file 1, appendix 1’).
Computation of variances for hazard ratios and relative
risks
Little information on the relative risks and hazard ratios
mentioned above is available in the literature. Accord-
ingly, previously published raw data had to be trans-
formed to be useful for our analysis. The following
paragraphs describe how these data from various
sources yielded values for the relative risks and hazard
ratios.
Computation of variance for the hazard ratio for people
under treatment
The hazard ratio for people under treatment was taken
from Murphy and colleagues [23]. Because relative risks
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scale, the variance of the parameter on a linear scale has
to be estimated. The variance of the logarithm of a vari-
able can be estimated using a second order Taylor series
expansion. Thus, we can describe a hazard ratio for
which only the variance of its natural logarithm is
known as follows:
Var HR
HR
Var HR
Var HR HR Var HR
[ln( )] [ ]
[] [ l n () ]


1
2
2
Computation of variance for the relative risk of death for
nonadherence
The relative risk of death for people not adhering to
treatment is only known as its logarithmic counterpart.
Since the value taken from Lima and colleagues [11]
represented the relative risk of people adhering to their
treatment, the relative risk used in our formula requires
the inverse of this parameter. The variance of the rela-
tive risk for nonadherence, RRna,c a nb ed e r i v e df r o m
the variance of the logarithm of the relative risk of mor-
tality for nonadherence using the following method:
Var RR Var
RR
RR
RR
a
na
na
na
[ln( )] ln 















 

 


 
1
1
2
2
V Var RR
RR
Var RR
Var RR RR Var
RR
na
na
na
na na
[]
[]
[]
ln(









1
1
2
2
n na
na a RR Var RR
)
[ln( )]





 
2
where RRa is the relative risk of mortality for people
who adhere to antiretroviral therapy.
Computation of variance for relative risk of nonadherence
due to alcohol
The odds ratio for adherence related to alcohol use pro-
vided by Hendershot and colleagues [18] can be trans-
formed into a relative risk function following two simple
steps:
￿ Take the inverse of the odds ratio to obtain the
odds ratio of nonadherence for drinkers compared
to nondrinkers.
￿ Compute the relative risk for nonadherence for
drinkers versus nondrinkers.
The propagation of variance needs to be estimated for
each of these steps. The variance of the first step can be
approximated in the same manner as the hazard ratio.
The relative risk for nonadherence of drinkers compared
to nondrinkers is then calculated as follows:
RR
OR
PP O R

  () 1
where OR is the odds ratio of nonadherence for drin-
kers compared to nondrinkers, and P is the proportion
of nonadherence among drinkers. Lacking the necessary
information about this proportion, we took the propor-
tion of nonadherence of the entire population as a con-
servative estimate of this value.
The variance of this relative risk can be computed
using the Taylor series approximation with two variables
as derived for the variance of PDT. In this case, the var-
iance is given by:
Var RR OR P D Var P D Var OR PO R [[ , ] ] [ ] [] 
22
with
D
P
PP O R
OR 

  
1
1
2 ()
and
D
OR OR
PP O R
P 

  
()
()
1
1
2
The above relations define the relative risks, hazard
ratio, and their respective variances, and allow us to
compute the AAF of HIV/AIDS deaths.
Results
Figure 2 shows the AAFs and their 95% uncertainty
intervals for the five African GBD regions, separated by
sex and age. Although the effect is small, an inspection
of the uncertainty intervals shows that alcohol has a
negative effect on the outcome of an HIV infection. Of
t h ef i v eA f r i c a nG B Dr e g i o n s ,o n l yt h eN o r t hA f r i c a /
Middle East region had strata where the 95% uncer-
tainty intervals crossed 0, with only the men in that
region aged 35 to 54 years exhibiting a significant posi-
tive AAF.
Overall, in Africa, men have higher AAFs than
women, with AAFs generally highest in people under 55
years of age; however, not all of these differences are
statistically significant. The highest AAFs are in sub-
Saharan Africa, East, where the AAF was 0.34 (95% CI:
0.12, 0.56) for men aged 15 to 34 years, and 0.27 (95%
CI: 0.09, 0.45) for men aged 35 to 54 years. In women,
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regions; however, unlike the men, the AAFs are very
similar for the East, South, and West regions.
Discussion
This method allows a systematic computation of partial
AAFs for HIV/AIDS in any given population, including
the 95% uncertainty intervals. Despite the limited infor-
mation available, the results show a clear negative
impact of alcohol on adherence to an antiretroviral
treatment regime and consequently on the outcome of
the disease, especially in the sub-Saharan regions of
Africa. Although the AAFs are relatively low, HIV/AIDS
was responsible for 58.5 million DALYs in 2004 [7],
indicating that the burden of alcohol-attributable nonad-
herence to HIV/AIDS treatment is substantial.
The very broad categories used to describe alcohol
consumption and adherence to antiretroviral therapy do
not allow us to distinguish between moderate and heavy
drinking or different percentages of nonadherence, and
future research will be necessary to estimate a more
accurate AAF for HIV/AIDS mortality. Ideally, AAFs
would be estimated by using a continuous distribution
of alcohol consumption and the risk relations for adher-
ence to antiretroviral treatment associated with each
level of consumption, as well as by specific patterns of
drinking, such as heavy occasional drinking [30]. Model-
ing alcohol consumption with these two dimensions
continuously and triangulating data obtained from sur-
veys with adult per capita consumption information
[31,32] are especially important for countries with high
variation in patterns of drinking among drinkers.
These results may not be relevant for all parts of
Africa. Many Africans completely abstain from alcohol,
while many of those who drink tend to do so heavily,
resulting in comparatively small variations in drinking
Figure 2 Proportions of deaths caused by nonadherence to antiretroviral therapy due to alcohol consumption with their 95%
uncertainty intervals for the five African GBD regions, by sex and age.
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default.asp. Since we expect alcohol consumed as part of
heavy drinking patterns to interfere more with antiretro-
viral treatment than moderate patterns of drinking
[18,33], our estimates of AAFs based on the dichoto-
mous variable of alcohol consumption (yes/no) consti-
tute conservative estimates of the alcohol-attributable
HIV/AIDS disease burden.
It is important to note that both the proportion of
drinkers as well the proportion of people on antiretro-
viral therapy influence the AAF. Indeed, even though
the proportion of drinkers in the sub-Saharan Africa,
South region, is lower than in the sub-Saharan Africa,
West region, the proportion of people in treatment is
larger in the South region, which yields a larger overall
AAF for this region. It is very likely that alcohol also
has an effect on the progress of the disease in people
without treatment that we did not estimate, but today’s
research does not allow us to deduce causality or quan-
tify such an effect [6]. Improving this situation by con-
ducting research to ascertain and quantify the effect of
alcohol use on the disease progression of HIV/AIDS-
related morbidity and mortality without antiretroviral
treatment should be a priority.
Conclusions
Although the presented method could be improved by
better definition and quantification of exposure, it pro-
vides an evidence-based conservative estimate of the
impact of alcohol use on HIV/AIDS mortality and high-
lights the importance of further research in this field. It
also points to the need to integrate alcohol prevention
measures [34] into the protocol for antiretroviral
treatment.
Additional material
Additional file 1: Appendix 1 outlines the derivation of the AAF
variance for HIV. The derivations of the variance of the multiplication of
two independent random variables and the derivations of the variances
of AdAF, NAAAF, and PDT, using Taylor Series expansions for one or
multiple variables, are described.
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